{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:50:40Z","timestamp":1791834640446,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R38HL143584"],"award-info":[{"award-number":["R38HL143584"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1274501"],"award-info":[{"award-number":["24CDA1274501"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI163081"],"award-info":[{"award-number":["U01AI163081"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL180499"],"award-info":[{"award-number":["R01HL180499"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK139321"],"award-info":[{"award-number":["R01DK139321"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejim.2026.107232","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:34:00Z","timestamp":1791459240000},"page":"107232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phenotypes of diabetic kidney disease and cardiovascular outcomes"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7695-4674","authenticated-orcid":false,"given":"Sophie E","family":"Claudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3458-0194","authenticated-orcid":false,"given":"Runqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-6570","authenticated-orcid":false,"given":"Insa M","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-2947","authenticated-orcid":false,"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8109-1420","authenticated-orcid":false,"given":"Anand","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4004-326X","authenticated-orcid":false,"given":"Sushrut S","family":"Waikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-6327","authenticated-orcid":false,"given":"Ashish","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejim.2026.107232_bib0001","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: a clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.ejim.2026.107232_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus\u2013related all-cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.ejim.2026.107232_bib0003","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.ajkd.2021.02.335","article-title":"Changes in GFR and albuminuria in routine clinical practice and the risk of kidney disease progression","volume":"78","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.ejim.2026.107232_bib0004","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejim.2026.107232_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.18808","article-title":"Concordance with screening and treatment guidelines for chronic kidney disease in type 2 diabetes","volume":"7","author":"Edmonston","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ejim.2026.107232_bib0006","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.mayocp.2020.07.037","article-title":"Adherence to chronic kidney disease screening guidelines among patients with type 2 diabetes in a US administrative claims database","volume":"96","author":"Folkerts","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.ejim.2026.107232_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/dme.70254","article-title":"Chronic kidney disease in type 2 diabetes in UK primary care: testing frequency, coding accuracy and clinical inertia","volume":"43","author":"Zafar","year":"2026","journal-title":"Diabet Med"},{"issue":"11","key":"10.1016\/j.ejim.2026.107232_bib0008","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1007\/s00125-018-4691-2","article-title":"Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicentre study","volume":"61","author":"Penno","year":"2018","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.ejim.2026.107232_bib0009","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2026.107232_bib0010","series-title":"National health and nutrition examination survey","year":"2023"},{"key":"10.1016\/j.ejim.2026.107232_bib0011","article-title":"UK Biobank Baseline assessment","author":"Biobank","year":"2022","journal-title":"About Our Data"},{"key":"10.1016\/j.ejim.2026.107232_bib0012","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M23-2814","article-title":"Association of albuminuria with chronic Kidney disease progression in persons with chronic Kidney disease and normoalbuminuria","volume":"177","author":"Verma","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2026.107232_bib0013","first-page":"1737","volume":"385","author":"Inker","year":"2021"},{"issue":"4","key":"10.1016\/j.ejim.2026.107232_bib0014","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.ejim.2026.107232_bib0015","doi-asserted-by":"crossref","DOI":"10.2202\/1557-4679.1104","article-title":"The comparison of alternative smoothing methods for fitting non-linear exposure-response relationships with Cox models in a simulation study","volume":"5","author":"Govindarajulu","year":"2009","journal-title":"Int J Biostat"},{"issue":"2","key":"10.1016\/j.ejim.2026.107232_bib0016","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ajkd.2021.11.011","article-title":"Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 Diabetes: findings from the Hong Kong Diabetes Biobank","volume":"80","author":"Jin","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1016\/j.ejim.2026.107232_bib0017","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.ejim.2026.107232_bib0018","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2337\/dc19-2049","article-title":"The prognosis of patients with type 2 diabetes and nonalbuminuric diabetic kidney disease is not always poor: implication of the effects of coexisting macrovascular complications (JDDM 54)","volume":"43","author":"Yokoyama","year":"2020","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ejim.2026.107232_bib0019","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure: JACC State-of-the-art review","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"151","key":"10.1016\/j.ejim.2026.107232_bib0020","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: a State-of-the-art review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejim.2026.107232_bib0021","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ajkd.2021.11.011","article-title":"Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 Diabetes: findings from the Hong Kong Diabetes Biobank","volume":"80","author":"Jin","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.ejim.2026.107232_bib0022","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ejim.2026.107232_bib0023","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2018111166","article-title":"Changes in albuminuria but not GFR are associated with early changes in kidney structure in type 2 diabetes","volume":"30","author":"Looker","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"5S","key":"10.1016\/j.ejim.2026.107232_bib0024","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ejim.2026.107232_bib0025","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.ejim.2026.107232_bib0026","doi-asserted-by":"crossref","unstructured":"Limonte CP, Schaub JA, Fallegger R, et al. Redefining kidney disease: clinico-pathological and molecular findings from the Kidney Precision Medicine Project. MedRxiv. Preprint posted online February 26, 2026. doi:10.64898\/2026.02.24.26347022.","DOI":"10.64898\/2026.02.24.26347022"},{"issue":"1","key":"10.1016\/j.ejim.2026.107232_bib0027","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/13696998.2023.2235922","article-title":"Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes","volume":"26","author":"Rossing","year":"2023","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.ejim.2026.107232_bib0028","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"Chronic Kidney disease and Risk Management: standards of Care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ejim.2026.107232_bib0029","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ejim.2026.107232_bib0030","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes management in Chronic Kidney Disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ejim.2026.107232_bib0032","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2018111166","article-title":"Changes in albuminuria but not GFR are associated with early changes in kidney structure in type 2 diabetes","volume":"30","author":"Looker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2026.107232_bib0033","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejim.2026.107232_bib0034","first-page":"149","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"130","author":"Neal","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejim.2026.107232_bib0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejim.2026.107232_bib0036","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"issue":"11 Pt 1","key":"10.1016\/j.ejim.2026.107232_bib0037","article-title":"Albuminuria in type 2 diabetes and risk of cardiorenal outcomes","volume":"4","author":"Parveen","year":"2025","journal-title":"JACC Adv"},{"issue":"13","key":"10.1016\/j.ejim.2026.107232_bib0038","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526005376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526005376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:37:38Z","timestamp":1791833858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526005376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":37,"alternative-id":["S0953620526005376"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107232","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypes of diabetic kidney disease and cardiovascular outcomes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107232"}}